Carmell Therapeutics, a Pittsburgh, PA-based company that manufactures novel blood plasma-based biomaterials that accelerate the repair of injured tissues, has closed a Series A financing of undisclosed amount.
The round was led by Harbor Light Capital Partners, with participation from Newlin Investment Company, the PLSG Accelerator Fund, Innovation Works, Ariel Savannah Angels, Blue Tree Allied Angels and individual investors.
The company intends to use the funds to establish a pilot manufacturing facility and collect data for early clinical validation for its first products.
Led by President and CEO Alan West, Carmell Therapeutics manufactures novel biomaterials from blood plasma containing a concentration of natural growth and regenerative factors to accelerate the repair of injured tissues. The company focuses on developing products to treat injuries to connective tissues (bone, tendons, ligaments, and cartilage).